# US 8,788,211 B2 · Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,788,211 B2 - Document ID: US8788211B2 - Status: Granted - Kind: B2 - Application number: 12/290,676 - Filed: 2008-10-31 - Published: 2010-05-06 - Granted: 2014-07-22 - Earliest claimed: 2008-10-31 - Assignees: The Invention Science Fund I, LLC - Applicants: Edward S. Boyden; Daniel B. Cook; Roderick A. Hyde; Eric C. Leuthardt; Nathan P. Myhrvold; Elizabeth A. Sweeney; Lowell L. Wood, Jr. - Inventors: Edward S. Boyden; Daniel B. Cook; Roderick A. Hyde; Eric C. Leuthardt; Nathan P. Myhrvold; Elizabeth A. Sweeney; Lowell L. Wood, Jr. - Web page: https://patentgrep.com/patent/US8788211B2 ## CPC - G01N 33/575: for cancer - A61B 17/3203: Fluid jet cutting instruments - G01N 33/57557: {of other specific parts of the body, e.g. brain} - G16H 10/20: for electronic clinical trials or questionnaires - G16H 20/13: delivered from dispensers - G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture - G16H 50/50: for simulation or modelling of medical disorders - A61B 18/02: by cooling, e.g. cryogenic techniques - A61B 2017/00022: {Sensing or detecting at the treatment site} - A61B 2017/00128: {related to intensity or progress of surgical action} - A61B 2034/101: {Computer-aided simulation of surgical operations} - A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. ## Claims ### Claim 1 A system, comprising: a computing device and a plurality of instructions that when executed on the computing device cause the computing device to generate output information, and direct a remote controlled delivery device to administer a plurality of frozen particle compositions in sequential order to a subject; the plurality of frozen particle compositions including at least two subsets of frozen particle compositions including at least one tracer agent, and different therapeutic agents, wherein the therapeutic agents include one or more of an anti-tumor agent, antimicrobial agent, anti-viral agent, analgesic, anesthetic, anti-inflammatory agent, vaccine, chemical debridement agent, immunogen, antigen, hormone, enzyme, cytokine, or anti-coagulant; the plurality of instructions including but not limited to: one or more instructions for comparing information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one subject as detected by the at least one tracer agent and information regarding at least one clinical outcome following receipt by the at least one subject of at least one subset of frozen particle composition; the output information being based on the comparison; and including at least one of a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination delivered, a code indicative of at least one therapeutic agent delivered; a code indicative of at least one diagnostic agent delivered; a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one delivered agent; a code indicative of at least one detection material delivered; a code indicative of the depth of penetration of a delivered agent; and further directing the remote controlled delivery device to adjust the administration of the sequential order of one or more subset of frozen particle compositions based on the comparison and real-time feedback control as determined by detection of the at least one tracer agent. ### Claim 2 (depends on 1) The system of claim 1, further including one or more instructions for determining at least one statistical correlation. ### Claim 3 (depends on 2) The system of claim 2, further including one or more instructions for using one or more of the at least one correlation to predict at least one clinical outcome regarding at least one second subject. ### Claim 4 (depends on 3) The system of claim 3, wherein the at least one second subject has not received at least one frozen particle composition. ### Claim 5 (depends on 3) The system of claim 3, further including one or more instructions for predicting at least one clinical outcome involving the at least one second subject, wherein the at least one second subject is a plurality of people; and segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. ### Claim 6 (depends on 3) The system of claim 3, wherein the at least one second subject is a plurality of people; and further including determining the eligibility of the at least one second subject for the at least one clinical trial. ### Claim 7 (depends on 1) The system of claim 1, further including one or more instructions for counting the occurrence of at least one clinical outcome. ### Claim 8 (depends on 1) The system of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding quantity of cells or tissue removed or destroyed. ### Claim 9 (depends on 1) The system of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one dimension of cellular, tissue, or other material removal or destruction. ### Claim 10 (depends on 9) The system of claim 9, wherein the information regarding at least one dimension of cellular, tissue, or other material removal or destruction includes information regarding at least one depth, width, or breadth of cellular, tissue, or other material removal or destruction. ### Claim 11 (depends on 1) The system of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding two or more subjects with one or more common attributes. ### Claim 12 (depends on 1) The system of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one cellular or tissue source. ### Claim 13 (depends on 12) The system of claim 12, wherein the information regarding at least one tissue source includes information regarding at least one abnormal cellular or tissue source. ### Claim 14 (depends on 12) The system of claim 12, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. ### Claim 15 (depends on 1) The system of claim 1, wherein at least one subset of frozen particle compositions further includes at least one of polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, diethyl ether, nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, chlorine, bromine, oxygen, air or argon. ### Claim 16 (depends on 1) The system of claim 1, wherein at least one frozen particle composition of the plurality includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. ### Claim 17 (depends on 1) The system of claim 1, wherein at least one frozen particle composition of the plurality includes one or more reinforcement agents. ### Claim 18 (depends on 1) The system of claim 1, wherein at least one frozen particle composition of the plurality includes one or more explosive materials. ### Claim 19 (depends on 1) The system of claim 1, wherein the receipt by the at least one subject of at least one frozen particle composition is pursuant to at least one clinical trial. ### Claim 20 (depends on 1) The system of claim 1, further including one or more instructions for creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving at least one frozen particle composition of the plurality. ### Claim 21 (depends on 1) The system of claim 1, further including one or more instructions for suggesting the inclusion of one or more of the at least one subject in at least one clinical trial. ### Claim 22 (depends on 1) The system of claim 1, further including one or more instructions for suggesting the exclusion of one or more of the at least one subject in at least one clinical trial. ### Claim 23 (depends on 1) The system of claim 1, wherein the at least one biological tissue includes at least one of a tooth, bone, connective tissue, adipose tissue, skin, scalp, hair, nail, nail bed, teeth, eye, tongue, tonsil, adenoid, liver, pancreas, stomach, blood vessel, heart, lung, brain, breast, kidney, bladder, urethra, ureter, gall bladder, uterus, ovary, oviduct, prostate, large intestine, small intestine, esophagus, oral cavity, nasal cavity, otic cavity, tumor, neoplastic tissue, or muscle tissue. ### Claim 24 (depends on 1) The system of claim 1, wherein the at least one subject includes at least one of a reptile, mammal, amphibian, bird, or fish. ### Claim 25 (depends on 24) The system of claim 24, wherein the at least one subject includes at least one of a pet, livestock, undomesticated herd animal, wild animal, or product animal. ### Claim 26 (depends on 24) The system of claim 24, wherein the at least one subject includes at least one of a human, sheep, goat, frog, dog, cat, rat, mouse, vermin, monkey, duck, horse, cow, pig, chicken, shellfish, fish, turkey, llama, alpaca, bison, wolf, fox, coyote, deer, rabbit, guinea pig, yak, chinchilla, mink, reindeer, raccoon, deer, elk, camel, donkey, or mule. ### Claim 27 (depends on 1) The system of claim 1, wherein the computing device is configured to communicate with a frozen particle composition generating apparatus. ### Claim 28 A system, comprising: a computing device and a plurality of instructions that when executed on the computing device cause the computing device to generate output information, and direct a remote controlled delivery device to administer a plurality of frozen particle compositions in sequential order to a subject; the plurality of instructions including but not limited to: one or more instructions for comparing information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one subject and information regarding at least one frozen particle composition involving the at least one biological tissue of at least one subject; the plurality of frozen particle compositions including at least two subsets having different therapeutic agents and at least one tracer agent, the therapeutic agents including one or more of an anti-tumor agent, antimicrobial agent, anti-viral agent, analgesic, anesthetic, anti-inflammatory agent, vaccine, chemical debridement agent, immunogen, antigen, hormone, enzyme, cytokine, or anti-coagulant; and one or more instructions for applying one or more comparisons to information regarding at least one aspect of cellular or tissue abrasion or ablation regarding a plurality of people as determined by detection of the at least one tracer agent; the output information being based on the comparison and real-time feedback control based on the detection of the at least one tracer agent, and includes at least one of a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination delivered, a code indicative of at least one therapeutic agent delivered; a code indicative of at least one diagnostic agent delivered; a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one delivered agent; a code indicative of at least one detection material delivered; a code indicative of the depth of penetration of a delivered agent; and further directing the remote controlled delivery device to adjust the sequential order administration of the at least one frozen particle composition based on the comparison and detection of the at least one tracer agent. ### Claim 29 (depends on 28) The system of claim 28, further including one or more instructions for segregating subject identifiers associated with the plurality of people in reference to at least one of the one or more applied comparisons. ### Claim 30 (depends on 28) The system of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding quantity of cells or tissue removed or destroyed. ### Claim 31 (depends on 28) The system of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one dimension of cellular, tissue, or other material removal or destruction. ### Claim 32 (depends on 31) The system of claim 31, wherein the information regarding at least one dimension of cellular, tissue, or other material removal or destruction includes information regarding at least one depth, width, or breadth of cellular, tissue, or other material removal or destruction. ### Claim 33 (depends on 28) The system of claim 28, further including one or more instructions for segregating individual identifiers associated with the plurality of people in reference to at least one characteristic shared by two or more subjects of the plurality of people. ### Claim 34 (depends on 28) The system of claim 28, wherein the at least one biological tissue is located in at least one of in situ, in vitro, in vivo, in utero, in planta, or ex vivo. ### Claim 35 (depends on 28) The system of claim 28, wherein the plurality of frozen particle compositions includes at least one frozen particle composition with at least one of an abrasive, reinforcement agent, or explosive. ### Claim 36 (depends on 28) The system of claim 28, wherein at least one frozen particle composition of the plurality includes at least one of nitrogen, argon, helium, air, oxygen, neon, xenon, krypton, chlorine, bromine, carbon dioxide, polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, or diethyl ether. ### Claim 37 (depends on 28) The system of claim 28, wherein the at least one biological tissue includes at least one of a tooth, bone, connective tissue, adipose tissue, skin, scalp, hair, nail, nail bed, teeth, eye, tongue, tonsil, adenoid, liver, pancreas, stomach, blood vessel, heart, lung, brain, breast, kidney, bladder, urethra, ureter, gall bladder, uterus, ovary, oviduct, prostate, large intestine, small intestine, esophagus, oral cavity, nasal cavity, otic cavity, tumor, neoplastic tissue, or muscle tissue.